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S_ary It has been suggested that tamoxifen may improve the efficacy of medical castration with
luteinising hormone-releasing hormone analogues, but very few data have so far been published concerning the
clinical and endocrinological activity of this therapeutic modality. In this phase II multicentre trial conducted
by the Italian Trials in Medical Oncology group (ITMO), 64 premenopausal patients with hormone receptor-
positive or unknown breast cancer were treated with monthly s.c. injections of goserelin 3.6 mg, in association
with a tamoxifen daily dose of 20 mg, as first-lie therapy for their advanced disease. All of the patients were
evaluable for efficacy and there was an overall response rate of 41% (95% confidence interval 28-52%), with
7 of the 26 responders achieving complete remission. The median time to response was 4 months (range 2- 17),
and the median response duration was 13 months (range 6-37 +). Better responses were observed in soft
tissues (51%); the response in visceral and bone metastases was respectively 19% and 37%. Serum concentra-
tions of gonadotrophins and oestradiol were significantly decreased by the treatment, oestrogen levels being
constantly suppressed to within the range observed in post-menopausal women. No significant change was
detected in serum testosterone levels. In our experience, although it was not associated with any increased
clinical efficacy, the concurrent use of goserelin and tamoxifen proved to be a feasible approach in the
management of premenopausal advanced breast cancer.
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Most circulating oestrogens in premenopausal woman are
synthesised in the ovary under the stimulatory control of
pituitary gonadotrophins, which is why the inhibition of
ovarian activity is thought to be a valuable approach in the
treatment of mammary carcinoma.
During the 1980s, a novel endocrine tool was developed
after the introduction of luteinising hormone-releasing hor-
mone (LH-RH) analogues, which provided a means for
decreasing circulating oestrogen levels without the need for
irreversible surgical oophorectomy (Santen et al., 1986).
In patients with premenopausal advanced breast cancer,
the clinical efficacy of a number of LH-RH analogues has
been reported (Klijn and de Jong, 1982; Harvey et al., 1985)
and, although the response rates for surgical and medical
forms of castration are similar, the use of these analogues
leads to a lower rate of morbidity. Goserelin is a potent
LH-RH analogue which can be easily administered by
means of the monthly injection of a depot formulation
(Matta et al., 1988).
Experience with tamoxifen therapy in young patients is
more limited than that acquired in post-menopausal women,
but the response to this agent has been reported to be similar
to that of oophorectomy (Buchanan et al., 1986); never-
theless, despite its antioestrogenic properties, many patients
on long-term tamoxifen therapy continue to have regular
ovulation and menstrual cycles (Ribeiro and Swindell, 1988).
It has been suggested that the association of an LH-RH
analogue and tamoxifen capable of inducing a so-called
'complete oestrogen blockade' (Klijn and de Jong, 1984)
would lead to fewer oestrogens being available for the
stimulation of breast cancer cell growth. The biological
assumption underlying the use of such a therapy is that of
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blocking ovarian steroid production with the analogue and,
at the same time, using the antioestrogen to counteract any
residual oestrogen action on cancer cells in an attempt to
obtain an increase in the rate and/or duration of response.
Given the potential benefits and the very few published
data concerning this therapeutic approach, the present phase
II trial was undertaken by our group with the aim of acquir-
ing further information on the efficacy and toxicity of com-
bined goserelin and tamoxifen treatment in patients with
previously untreated premenopausal advanced breast cancer.
An attempt was also made to determine the effects of the
therapy on the patients' hormonal environment.
Paiet and1
Patients
Sixty-four consecutive unselected premenopausal patients
with advanced breast cancer entered this multicentre study
sponsored by the Italian Trials in Medical Oncology (ITMO)
group and coordinated by Medical Oncology Division B of
Milan's Istituto Nazionale Tumori. The patients were con-
sidered eligible providing they had a diagnosis of advanced
breast ancer with measurable lesions, positive hormone
receptors [oestrogen receptor (ER) > 10 and/or progesterone
receptor (PgR) >25 fmolmg-' cytosol protein] or a disease-
free interval (DFI) > 2 years and a performance status of
<2 (ECOG scale) and had not previously received any
systemic therapy for their advanced disease. Previous adju-
vant cytotoxic chemotherapy for primary disease was permit-
ted. Women were defined as premenopausal if they were
actively menstruating or if less than 1 year had elapsed since
their last menstrual period; patients with chemotherapy-
induced amenorrhoea were considered premenopausal if they
were younger than 50 years and had levels of both gonado-
trophins in the premenopausal range (<40 IU 1`). Meta-
stases occupying more than a third of the liver, lung lym-
phangitic metastases or brain dissemination were considered
exclusion criteria. Patients with pleural effusion or bone
blastic metastases as the only manifestation of disease wereGoseren p-istbmn in p _eien-mus breast cander
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excluded, as were those on concomitant anti-cancer therapies,
other than limited radiotherapy fields on unevaluable bone
lytic painful sites. Informed consent was obtained from all
subjects before starting therapy, and the study was approved
by the bioethics committee. Upon entry, patients were evalu-
ated for disease extension by means of clinical examination,
chest and skeletal radiographs, liver ultrasound or computer-
ised tomographic scans, whole blood cell counts and blood
chemistry.
Dose and schedule
A depot formulation of goserelin 3.6 mg was administered by
subcutaneous implantation in the abdominal wall every 4
weeks in an out-patient setting. Tamoxifen was self-admin-
istered at a total daily dose of 20 mg. At the time of each
clinical examination, the physician questioned the patients
directly in order to check that they were taking the drug
regularly. In patient with a normal menstrual cycle, treat-
ment was started in the early follicular phase. The treatment
was continued until there were no signs of disease progres-
sion, providing no severe adverse effects appeared.
Response assessment
The initial assessment of response was after 2 months of
treatment. Clinical examinations were repeated monthly; the
other investigations after 2 months of therapy and subse-
quently at 3 monthly intervals. If the treatment was stopped
for any reason during the first 2 months of therapy, the
patient was considered as a treatment failure but evaluable in
terms of tumour response.
Response was assessed according to UICC criteria (Hay-
ward et al., 1977), an objective response being defined as
either complete (CR) or partial remission (PR). In particular,
CR for bone disease was defined as the disappearance of lytic
metastases; partial recalcification was considered a PR. In no
case was pain relief considered an objective response.
In the case of treatment discontinuation, patients were
followed every 2 months in order to record their survival
time. Toxicity was evaluated at each visit according to WHO
(1979) criteria.
Endocrine investigations
Blood samples for hormonal analysis were taken at baseline
(pretreatment) and 2, 6 and 12 months after starting therapy.
The samples were collected at the same time of day for each
patient throughout the study (between 9.00 and 11.00 h) and
the serum was separated and stored at - 20-C until assay.
Oestradiol (E2) was measured using a radioimmunoassay kit
obtained from Diagnostic Products (Los Angeles, CA, USA),
which had a sensitivity of 5.5 pmol I-1 and intra- and inter-
assay coefficients of variation of 7% and 8.9% respectively.
Follicle-stimulating hormone (FSH), luteinising hormone
(LH) and testosterone (T) levels were determined as
previously described (Bajetta et al., 1994a).
For each hormone, all of the samples from the same
patient were analysed in the same assay batch. All endocrine
evaluations were performed at the Laboratory of Endocrin-
ology of Milan's Istituto Nazionale Tumori.
Analysis of results
The study was planned according to the Simon's optimal
two-stage design (Simon, 1989), in order to test the hypo-
thesis that the true response probability was less than 40%
against the alternative hypothesis of a response probability of
more than 60%. With type I and II error probability levels of
5% and 10% respectively, this design implies that the treat-
ment must be rejected if fewer than 11 responses are observ-
ed at the end of the first stage (25 patients) or fewer than 32
at the end of the second stage (total of 66 patients).
The response duration was calculated from the onset of
disease regression to the time of progression or last follow-up
visit. Survival curves for the times to death and treatment
failure (TTF) were obtained using the Kaplan-Meier
method. 1TF was calculated as the time elapsing from the
start of treatment to the date of treatment discontinuation
for any reason.
Quantitative endocrine data are reported as means ± s.e.m.
The values of each analyte at baseline and at the time of the
last available sampling were compared using the Wilcoxon
signed-rank test. The adopted significance level was 5%.
Results
Clinical results
Sixty-four premenopausal women with previously untreated
advanced breast cancer entered this trial between January
1991 and March 1993. Although two subjects were with-
drawn early after refusing the second injection of goserelin,
all of the 64 women enrolled were considered evaluable
according to the intention to treat principle. The main
patient characteristics of the enrolled patients are sum-
marised in Table I.
After a median treatment duration of 11 months (range
1-39), objective responses included seven CRs (11%) and 19
PRs (30%), the overall response rate being 41% (95% confi-
dence interval 28-52%). In women with a normal menstrual
cycle, delayed amenorrhoea beyond the second month of
therapy was observed in only one subject, in whom three
goserelin administrations were required to induce amenor-
rhoea.
The median age on entry of the responding patients was 41
years (range 29-52), and all but two had a performance
status < 1 (ECOG scale). With the exception of two patients
in CR with spontaneous amenorrhoea lasting less than 1
year, all of the responders were actively menstruating at the
start of therapy. With regard to the hormone receptor status
of the primary or recurrent tumour, 20 responsive patients
(77%) had both ER- and PgR-positive tumours; one patient
in CR and three in PR were only ER positive, and a further
two patients in PR had an unknown receptor status.
Sixteen of the 26 responders (62%) had a DFI > 2 years.
Of the women who experienced an objective response, 15
(58%) had previously received adjuvant chemotherapy.
Table I Main patient characteristics
Characteristic Number
Entered/evaluable 64/64
Median age (range) 43 (29-52)
ECOG performance status
< 1/2 59/5
DFI (years)
<2/>,2 18/46
Receptor status
ER positive 52 (81%)
ER unk-nown 12
PgR positive 42 (66%)
PgR negative 11
PgR unknown 11
Menstrual status
Regular menses 54 (84%)
Spontaneous amenorrhoea 6
Drug-induced amenorrhoea 4
Dominant disease
Soft tissues 35
Viscera 16
Bone 35
Number of disease sites
44 (69%)
,_2 20 (31%)
Previous adjuvant chemotherapy 32 (50%)GR i p- o.ud.in
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When analysing the response rate by disease location, the
vast majority of objective remissions occurred in soft tissues
(14 CRs + four PRs; overall resonse rate 51%). It is worth
poiting out that all of the patients achiving CR had only
soft-tissue metaases, suggesting that the benefits of therapy
were greater in the patients with a better prognosis. Only
three tumour regressions (one CR + one PR on lung and one
CR on pleura; overall response rate 19%) were observed in
viseral locations, with none of seven liver metastatic sites
achieving an objective response. The bone lytic metastases
showed only partial recakification in 37% of the cases. An
objective response was documented in six patients with more
than one disease location.
The median time to response was 4 months (range 2-17);
the median response duration was 24 months (range 7-37 +)
in the case of CR and 12 months (range 6-30 +) for PR (13
months for CR + PR). At the time of this analysis, nine
patients (two in CR and seven in PR) were still continuing
treatment. The TTF and survival curves are shown in Figures
1 and 2.
Compliance with treatment was highly satisfactory, and
both drugs were an d regularly as scheduled in all
patints. In the 62 patients evaluable for toxicty, the com-
bination was extremely well tolerated; the main side-effect
was hot flushes, which occurred in 74% of patients but were
described as severe by only two women. A reduction in libido
was reported by 26% of patients. No patient was withdrawn
from the study because of pharmacological ide-effects.
Endocrine results
Data on hormone levels were mising for many patients
because blood samples were not available for logistic reasons.
Therefore the endocrine effects of the association during the
first 12 months of treatment were assd in only 34 women.
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Serum LH fell below the sensitivity of the method used
(0.5 IU 1-') in all patients from month 2 onwards. Pretreat-
ment FSH levels [25.59 ± 4.32 (mean ± s.e.m.) IUIl- were
also decreased significntly (P = 0.0001) during therapy, fal-
ling to 2.64 ± 0.19 after 8 weeks, and rmaining unchanged
subsequently (2.32 ± 0.16 IUl- and 2.21 ± 0.22 IU - at 6
and 12 months respectively).
The combination induced a persisent suppresson of E2
levels within the range of values observed in castrated or
post-menopausal women (<70pmol 1') in all patients. Basal
oestrogen levels (191.06 ± 62.29pmol 1') were significantly
decreased by an average of 92% over a 12 month period
(P = 0.0001).
Serum T levels did not appear to be affected by treatment
(P=0.10), mean androgen value being 1.14±0.17nmoll'
after 12 months compared with 1.19 ± 0.10nmol 1 at start-
ing therapy.
Convincing evidence exists that LH-RH analogue goserelin
is effective in premenopausal patients with advanced breast
cancer (Blamey et al., 1992), but castration levels of E2 are
only reached after 3-4 weeks compared with 2-7 days after
surgical oophorectomy (Beksac et al., 1983). Furthermore,
treatment with the analogue makes menstruating patients
post-menopausal without interfering with androgen precursor
aromatisation in peripheral tissues, a process believed to be
the major source of circulating oestrogens in post-meno-
pausal woman (Santen, 1990).
The role of tamoxifen in the managemt of premeno-
pausal breast cancer does not appear to be as well established
(Sunderland and Osborne, 1991), although the increased oes-
trogen levels reported in young patients on tamoxifen
therapy seem to imply a direct gonadal effect of the drug
(Manni and Pearson, 1980). This ovarian stimulation could
theoretically reverse the inhibitory effect of tamoxifen on the
growth of breast cancer cells, and thus decrease anti-tumour
activity.
In the present study, the combination of goserelin and
tamoxifen therapy led to a remission rate of41%, the median
duration of response being 13 months. Although our clinical
results in terms of remission rate and response duration are
similar to those reported for goserelin alone (response rates
ranging from 33% to 45% and median response durations
ranging from 8 to 15 months; Dixon et al., 1990; Kaufinann
et al., 1991; Blamey et al., 1992; Bajetta et al., 1994b), it
remains an open question whether tamoxifen may offer any
advantage for patients treated with medical castration by the
analogue. No prospective study aesing the efficacy of the
combination has yet been published although, in a retrospec-
tive study of 50 patients receiving the combination, an
overall response rate of only 18% was reported; a further
30% of patients showed stable disease, but no significant
survival difference between these two response groups was
observed (Dixon et al., 1991). Recently, updating the results
of a large ongoing randomised trial comparing goserelin with
goserelin plus tamoxifen therapy, Jonat et al. (1994) have
reported that after a median follow-up of23 months only the
time to first progression was significantly longer in the com-
bination group (7 vs 6 months), and that there was no
significant difference in either the response rate or survival.
No endocrine antagonistic interaction between goserelin
and tamoxifen was observed in our study, in agreement with
previously reported data (Walker et al., 1989). No patient
actively menstruating at the start of therapy continued to
have normal cycles or experienced a return to menses on
treatment, and so the combination led to a profound sup-
pression of peripheral gonadotrophin and E2 concentrations
(such hypogonadotrophic inhibition of oestrogen ovarian
production being ent over time). Furthermore, serum
FSH values did not show any tendency to increase on long-
term therapy, as has been observed with goserelin alone
(Bajetta et al., 1994a), the association proving to be more
1
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effective in suppressing serum levels of this hormone. It must
be emphasised that FSH stimulates premenopausal oestrogen
synthesis by increasing the generation of molecules of the
aromatase enzyme in ovarian granulosa cells (Santen, 1990).
In conclusion, in this prospective trial, the association of
goserelin and tamoxifen proved to be a feasible treatment: it
was effective in terms of the endocrine changes induced in the
host and was not associated with any increased toxicity.
Although our clinical data show that the concurrent use of
goserelin and tamoxifen does not appear to provide better
results than the analogue alone in the palliation of advanced
breast cancer in premenopausal patients, it is necessary to
await publication of the definitive results of large well-
controlled randomised studies before it can be reliably con-
cluded that goserelin and goserelin plus tamoxifen are
equivalent therapies, or whether the association may lead to
an improvement in survival, which is a more important
indicator of true patient benefit. This latter aspect would also
be more relevant in view of the renewed interest in ovarian
ablation as adjuvant treatment in primary breast cancer,
although a higher risk of endometrial cancer has also been
reported in tamoxifen users (van Leeuwen et al., 1994).
Referews
BAJETTA E, ZILEMBO N, BUZZONI R, CELIO L, ZAMPINO MG,
COLLEONI M, ORLANA S, ATI-TLI A, SACCHINI V AND MARTIN-
ETrl A. (1994a). Goserelin in premenopausal advanced breast
cancer. clinical and endocrine evaluation of responsive patients.
Oncology, 51, 262-269.
BAJETMA E, CELIO L, ZILEMBO N, BONO A, GALLUZZO D, ZAM-
PINO MG, LONGHI A, FERRARI L AND BUZZONI R. (1994b).
Ovarian function suppression with the gonadotrophin releasing
hormone (GnRH) analogue goserelin in premenopausal advanced
breast cancer. Tunori, 80, 28-32.
BEKSAC MS, KISNISCI HA, CAKAR AN AND BEKSAC M. (1983).
The endocrinological evaluation of bilateral and unilateral
oophorectomy in premenopausal women. Int. J. Fertil., 28, 219.
BLAMEY RW, JONAT W, KAUFMANN M, BLANCO AR AND NAMER
M. (1992). Goserelin depot in the treatment of premenopausal
advanced breast cancer. Eur. J. Cancer, 28, 810-814.
BUCHANAN RB, BLAMEY RW, DURRANT KR, HOWELL A, PATER-
SON AG, PREECE PE, SMITH DC, WILLIAMS CJ AND WILSON
RG. (1986). A randomized comparison of tamoxifen with surgical
oophorectomy in premenopausal patients with advanced breast
cancer. J. Clii. Oncol., 4, 1326-1330.
DIXON AR, ROBERTSON JFR, JACKSON L, NICHOLSON RI,
WALKER KJ AND BLAMEY RW. (1990). Goserelin (Zoladex) in
premenopausal advanced breast canr: duration of response and
survival. Br. J. Cancer, 62, 868-870.
DIXON AR, JACKSON L, ROBERTSON JFR, NICHOLSON RI AND
BLAMEY RW. (1991). Combined gosrlin and tamoxifen in pre-
menopausal advanced breast cancer: duration of response and
survival. Eur. J. Cancer, 27, 806-807.
HARVEY HA, LIPTON A, MAX DT, PEARLMAN HG, DIAZ-PERCHES
R AND DE LA GARZA J. (1985). Medical castration produced by
the GnRH analogue leuprolide to treat metastatic breast cancer.
J. Clui. Oncol., 3, 1068-1072.
HAYWARD JL, RUBENS RD, CARBONE PP, HEUSON JC, KUMAOKA
S AND SEGALOFF A. (1977). Assessment of response to therapy
in advanced breast cancer. Br. J. Cancer, 35, 292-298.
JONAT W, KAUFMANN M, BLAMEY RW, HOWELL A, COLLINS JP,
COATES A, EIERMANN W, JAENICKE F, NJORDENSKOLD B,
FORBES J AND KOLVENBAG G. ON BEHALF OF THE ZOLADEX
TRIALIST GROUP. (1994). A randomised trial comparing Zoladex
(goserelin) with Zoladex plus Nolvadex (tamoxifen) as first line
treatment for premenopausal advanced breast cancer. Proc. Am.
Soc. Clin. Oncol., 13, 58.
KAUFMANN M, JONAT W, SCHACHNER-WUNSCHMANN E, BAS-
TERT G, MAASS H. ON BEHALF OF THE COOPERATIVE GER-
MAN ZOLADEX SrUDY GROUPS. (1991). The depot GnRH
analogue goserelin in the treatment of premenopausal patients
with metastatic breast cancer - a five-year experience and further
endocrine therapies. Onkologie, 22, 23-29.
KLIJN JGM AND DE JONG FH. (1982). Treatment with a luinizing
hormone-releasing analogue (Buserelin) in premenopausal
patients with metastatic breast cancer. Lancet, L 1213-1216.
KLUJN JGM AND DE JONG FH. (1984). Long-term treatment with the
LH RH-agonist buserelin (HOE 766) for metastatic breast cancer
in single and combined drug regimens. In LH-RH and its Analo-
gues, LaBrie F, Belanger A and Dupont A. (eds) pp. 425-437.
Elsevier: Amsterdam.
MANNI A AND PEARSON OH. (1980). Antiestrogen-induced remis-
sions in premenopausal women with stage IV breast cancer:
effects on ovarian function. Cancer Treat. Rep., 64, 779-785.
MA1TA WHM, SHAW RW AND BURFORD GD. (1988). Endocrino-
logic and clinical evaluation following a single administration of
a gonadotrophin-releasing hormone agonist (Zoladex), in a depot
formulation, to premenopausal women. Fertil. Steril., 49,
163-165.
RIBEIRO G AND SWINDELL RI (1988). The Christie Hospital adju-
vant tamoxifen trial - status at 10 years. Br. J. Cancer, 57,
601-603.
SANTEN RJ. (1990). Clnical use of aromatase inhibitors: current
data and future perspectives. J. Enzyme Inhibit., 4, 79-99.
SANTEN RJ, MANNI A AND HARVEY H. (1986). Gonadotropin
rekasing hormone (GnRH) analogs for the treatment of breast
cancer and prostatic carcinoma. Breast Cancer Res. Treat., 7,
129-145.
SIMON R. (1989). Optimal two-stage designs for phase II clinical
trials. Controlled Clin. Trials, 10, 1-10.
SUNDERLAND MC AND OSBORNE CK. (1991). Tamoxifen in pre-
menopausal patients with metastatic breast cancer: a review. J.
Clin. Oncol., 9, 1283-1297.
VAN LEEUWEN FE, BENRAADT J, COEBERGH JWW, KIEMENEY
LALM, GIMBRERE CHF, OTTER R, SCHOUTEN UJ, DAMHUIS
RAM, BONTENBAL M, DIEPENHORST FW, VAN DEN BELT-DUSE-
BOUT AW AND VAN TINTEREN H. (1994). Risk of endometrial
cancer after tamoxifen treatment of breast cancer. Lncet, 343,
448-452.
WALKER KJ, WALKER RF, TURKES A, ROBERTSON JFR, BLAMEY
RW, GRIFFITHS K AND NICHOLSON RI. (1989). Endocrine
effects of combination antioestrogen and LH-RH agonist
therapy in premnopausal patients with advanced breast cancer.
Eur. J. Cancer Clin. Oncol., 25, 651-654.
WHO. (1979). WHO Handbook for Reporting Results of Cancer
Treatment, World Health Organization: Geneva.